METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis

The Physician and Sportsmedicine
Rudy M Haddad, Christie M Ballantyne

Abstract

PRACTICE PEARL The data from the METEOR trial show that asymptomatic low-risk patients treated with rosuvastatin have a reduction in progression of carotid intima-media thickness (CIMT) over 2 years versus placebo. Original Article Crouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.

References

Feb 21, 1998·Annals of Internal Medicine·H N HodisS P Azen
Jun 12, 2003·Journal of the American College of Cardiology·Richard C PasternakNancy Houston-Miller
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators
Mar 15, 2006·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN ASTEROID Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·John R CrouseUNKNOWN METEOR Study Group
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Jan 28, 2009·Circulation·Vijay Nambi, Christie M Ballantyne
Dec 17, 2009·The American Journal of the Medical Sciences·Carl J LavieJames H O'Keefe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

© 2021 Meta ULC. All rights reserved